Posted by Admin
Post Date : Friday June 29 2007

RR is 72 year old woman that was diagnosed in October 2004 with non small cell lung (NSCLC) cancer stage 2. The mass in her left lobe measured 2.8 cm on a CT scan in 9/04. The CT scan also revealed a pretracheal adenopathy measuring up to 1.4 cm, an infracarinal adenopathy measuring 1.9 cm, a right hilar adenopathy measuring 1.4 cm and a left hilar lymph node measuring 1.5 cm. Her PET scan also revealed uptake in the upper left lung and lymph nodes confirming cancer activity. Her biopsy in 10/04 confirmed NSCLC. She started taking Poly-MVA on 10/08/04 and quickly got up to 8 teaspoons per day. The lung cancer was treated surgically in November 23, 2004 by removing the entire section of the upper left lung and the chest tube. Three lymph nodes were removed dissected and found to be benign. After surgery her oncologist insisted that she follow up with either Iressa or chemotherapy. She refused (Iressa was taken off the market shortly after) to take either one. Her oncologist dismissed her as a patient and refused to treat her if she “didn’t take what he recommended.” She quickly found other physicians that would monitor her progress. Since her diagnosis in October 2004, she has PET scans approximately every 6 months. Each one has been completely clear with no uptake noted. Her CEA has dropped overtime as follows (normal range 0.0-3.0 ng/ml):

3/16/05 - 1.1
6/8/05 - 0.8
3/15/06 - 0.7
9/18/06 - 0.6

Her Karnofsky score (no complaints, no evidence of disease) is 100%. She leads a full and active life. She remains on 2 teaspoons of Poly-MVA per day. If her CEA begins to rise or there is any evidence of recurrence on a PET scan or other imaging data she intends to resume 8 teaspoons per day or more of the Poly-MVA as her treatment.

Case study written by Dr. Shari Lieberman as a part of the Poly-MVA Best Case Series.